EcoDrugPlus

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion

Ensembl ID : ENSPPYG00000038797
Gene Symbol: FAU
4 Cross references
251 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Fxyd Domain Containing Ion Transport Regulator 2

Ensembl ID : ENSPPYG00000003916
Gene Symbol: FXYD2
5 Cross references
74 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSPPYG00000016930
Gene Symbol: FYN
5 Cross references
261 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

G Protein-Coupled Receptor 119

Ensembl ID : ENSPPYG00000020716
Gene Symbol: GPR119
5 Cross references
174 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

G Protein-Coupled Receptor 84

Ensembl ID : ENSPPYG00000004602
Gene Symbol: GPR84
5 Cross references
124 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSPPYG00000010900
Gene Symbol: HCK
5 Cross references
205 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Il2 Inducible T Cell Kinase

Ensembl ID : ENSPPYG00000015986
Gene Symbol: ITK
5 Cross references
207 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Janus Kinase 1

Ensembl ID : ENSPPYG00000001270
Gene Symbol: JAK1
5 Cross references
236 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Janus Kinase 2

Ensembl ID : ENSPPYG00000019243
Gene Symbol: JAK2
4 Cross references
265 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Janus Kinase 3

Ensembl ID : ENSPPYG00000009724
Gene Symbol: JAK3
5 Cross references
103 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Kit Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSPPYG00000014766
Gene Symbol: KIT
5 Cross references
265 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Kras Proto-Oncogene, Gtpase

Ensembl ID : ENSPPYG00000041739
Gene Symbol: KRAS
4 Cross references
201 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).